ATE482233T1 - Inhibitoren des memapsin 2 und ihre verwendung - Google Patents

Inhibitoren des memapsin 2 und ihre verwendung

Info

Publication number: ATE482233T1
Authority: AT; Austria
Prior art keywords: memapsin; substrate; ala; bond; leu
Prior art date: 1999-06-28

Application number

AT00943236T

Other languages

English (en)

Inventor

Jordan Tang

Lin Hong

Arun Ghosh

Xinli Lin

Gerald Koelsch

Original Assignee

Oklahoma Med Res Found

Univ Illinois

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-28

Filing date

2000-06-27

Publication date

2010-10-15

2000-06-27 Application filed by Oklahoma Med Res Found, Univ Illinois filed Critical Oklahoma Med Res Found

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE482233T1 publication Critical patent/ATE482233T1/de

Links

102100021257 Beta-secretase 1 Human genes 0.000 title abstract 9
101710150192 Beta-secretase 1 Proteins 0.000 title abstract 8
239000003112 inhibitor Substances 0.000 title abstract 4
239000000758 substrate Substances 0.000 abstract 9
NIOCOJFPGCXNKL-ZKZXETMPSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-4-amino-1-[[(4s,5s,7r)-8-[[(2s)-1-[[(2s)-4-carboxy-1-[[(1s)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-ox Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NIOCOJFPGCXNKL-ZKZXETMPSA-N 0.000 abstract 4
108010011140 OM99-2 Proteins 0.000 abstract 4
238000000034 method Methods 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
238000002050 diffraction method Methods 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Public Health (AREA)
Crystallography & Structural Chemistry (AREA)
Analytical Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00943236T 1999-06-28 2000-06-27 Inhibitoren des memapsin 2 und ihre verwendung ATE482233T1 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US14136399P	1999-06-28	1999-06-28
US16806099P	1999-11-30	1999-11-30
US17783600P	2000-01-25	2000-01-25
US17836800P	2000-01-27	2000-01-27
US21029200P	2000-06-08	2000-06-08
PCT/US2000/017742 WO2001000665A2 (en)	1999-06-28	2000-06-27	Inhibitors of memapsin 2 and use thereof

Publications (1)

Publication Number	Publication Date
ATE482233T1 true ATE482233T1 (de)	2010-10-15

Family

ID=27538142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00943236T ATE482233T1 (de)	1999-06-28	2000-06-27	Inhibitoren des memapsin 2 und ihre verwendung

Country Status (9)

Country	Link
US (7)	US6545127B1 (de)
EP (2)	EP1196609A2 (de)
JP (2)	JP4484410B2 (de)
CN (1)	CN1379819A (de)
AT (1)	ATE482233T1 (de)
AU (2)	AU5771500A (de)
CA (2)	CA2374610A1 (de)
DE (1)	DE60045005D1 (de)
WO (2)	WO2001000665A2 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9701684D0 (en)	1997-01-28	1997-03-19	Smithkline Beecham Plc	Novel compounds
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CA2343004A1 (en)	1998-09-24	2000-03-30	Pharmacia & Upjohn Company	Alzheimer's disease secretase
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7115410B1 (en)	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
GB2364059B (en)	1999-02-10	2004-01-14	Elan Pharm Inc	Beta-Secretase enzyme compositions and methods
JP4484410B2 (ja) *	1999-06-28	2010-06-16	オクラホマメディカルリサーチファウンデーション	メマプシン２のインヒビターおよびその使用
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
GB9924957D0 (en) *	1999-10-21	1999-12-22	Smithkline Beecham Plc	Novel treatment
GB9925136D0 (en) *	1999-10-22	1999-12-22	Smithkline Beecham Plc	Novel treatment
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
WO2001053255A1 (en) *	2000-01-24	2001-07-26	Merck Sharp & Dohme Limited	Gamma-secretase inhibitors
ES2287044T3 (es) *	2000-01-25	2007-12-16	Oklahoma Medical Research Foundation	Procedimiento universal para el replegamiento de proteinas recombinantes.
ATE343562T1 (de)	2000-03-23	2006-11-15	Elan Pharm Inc	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1299352B1 (de)	2000-06-30	2005-12-28	Elan Pharmaceuticals, Inc.	Verbindungen zur behandlung der alzheimerischen krankheit
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP2004504018A (ja) *	2000-07-19	2004-02-12	ファルマシア・アンド・アップジョン・カンパニー	β−セレクターゼ活性の基質およびアッセイ
EP1327143B1 (de) *	2000-09-22	2007-02-28	Wyeth	Kristallstruktur von bace und verwendungen dafür
US7601528B1 (en)	2000-12-23	2009-10-13	Elan Pharmaceuticals, Inc.	Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7806980B2 (en)	2000-12-23	2010-10-05	Elan Pharmaceuticals, Inc.	Method for crystallizing human beta secretase in complex with an inhibitor
US7217556B1 (en)	2000-12-23	2007-05-15	Pfizer Inc	Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US20040121947A1 (en) *	2000-12-28	2004-06-24	Oklahoma Medical Research Foundation	Compounds which inhibit beta-secretase activity and methods of use thereof
EP1233021A3 (de) *	2001-02-20	2002-11-20	Pfizer Products Inc.	Inhibitor des Beta-amyloid spaltenden Enzyms
CN100582226C (zh) *	2001-02-23	2010-01-20	Dsmip资产有限公司	编码新蛋白水解酶的新基因
US7524668B1 (en)	2001-05-10	2009-04-28	Elan Pharmaceuticals, Inc.	Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7384773B1 (en) *	2001-05-10	2008-06-10	Pfizer Inc	Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7196163B2 (en)	2001-05-22	2007-03-27	Merk & Co., Inc.	Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
CA2448253A1 (en)	2001-05-25	2002-11-28	Genset S.A.	Human cdnas and proteins and uses thereof
US7361688B2 (en) *	2001-06-11	2008-04-22	Elan Pharmaceuticals, Inc.	Substituted aminoalcohols useful in treatment of Alzheimer's disease
BR0210721A (pt)	2001-06-27	2004-07-20	Elan Pharm Inc	Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
WO2003012089A2 (en) *	2001-07-26	2003-02-13	Astex Technology Ltd	Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
US7186539B1 (en) *	2001-08-31	2007-03-06	Pharmacia & Upjohn Company	Method for refolding enzymes
US20060234944A1 (en) *	2001-10-23	2006-10-19	Oklahoma Medical Reseach Foundation	Beta-secretase inhibitors and methods of use
EP1448218A4 (de) *	2001-10-23	2009-01-14	Oklahoma Med Res Found	Beta-secretase-hemmer und anwendungsverfahren
AU2002351009A1 (en) *	2001-11-06	2003-05-19	Decode Genetics Ehf.	Nucleic acids encoding proteases
CH698246B1 (de) *	2001-12-20	2009-06-30	Hoffmann La Roche	Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
WO2003072733A2 (en)	2002-02-21	2003-09-04	Pharmacia & Upjohn Company	Modified bace
WO2003074046A1 (fr)	2002-03-01	2003-09-12	Takeda Chemical Industries, Ltd.	Antidepresseur
US7442537B1 (en)	2002-05-10	2008-10-28	Elan Pharmaceuticals, Inc.	Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US7205336B2 (en)	2002-05-17	2007-04-17	Merck & Co., Inc.	β-secretase inhibitors
US7166454B1 (en)	2002-05-24	2007-01-23	Schering Corporation	Codon-optimized β-secretase and methods of refolding and processing
US6746303B2 (en)	2002-05-31	2004-06-08	Mattel, Inc.	Flexible toy figure with wire armature
US20040096950A1 (en) *	2002-07-26	2004-05-20	Vuillard Laurent Michel Marie	Crystal structure of beta site APP cleaving enzyme (BACE) and methods of use thereof
US20050074456A1 (en) *	2002-12-04	2005-04-07	Marcus Ballinger	Constructs for homogenously processed preparations of beta site APP-cleaving enzyme
US7371853B2 (en)	2003-01-07	2008-05-13	Merck & Co., Inc.	Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease
US7482136B2 (en)	2003-05-02	2009-01-27	Elan Pharmaceuticals, Inc.	Glycosylation variants of BACE
US7291620B2 (en)	2003-06-30	2007-11-06	Merck + Co., Inc.	N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
CA2530006A1 (en)	2003-07-01	2005-01-20	Merck & Co., Inc.	Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
AU2004277981B2 (en)	2003-10-03	2009-10-01	Merck & Co., Inc.	Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease
FR2860796B1 (fr) *	2003-10-14	2006-02-10	Centre Nat Rech Scient	Procede de dissociation de la molecule d'hemoglobine extracellulaire d'arenicola marina, chaines proteiques constituant ladite molecule et sequences nucleotidiques codant pour lesdites chaines proteiques
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US20060019368A1 (en) *	2004-07-20	2006-01-26	Marcus Ballinger	Constructs for homogenously processed preparations of beta site APP-cleaving enzyme
CA2589860A1 (en) *	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
WO2006099379A2 (en) *	2005-03-14	2006-09-21	Transtech Pharma, Inc.	Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
EP1866034A1 (de)	2005-03-30	2007-12-19	Boehringer Ingelheim International GmbH	Substituierte 1,2-ethylendiamine, arzneimittel mit dieser verbindung, deren verwendung und deren herstellungsverfahren
AU2006279896A1 (en) *	2005-08-10	2007-02-22	Oklahoma Medical Research Foundation	Truncated memapsin 2 for use for treating Alzheimer's disease
CA2618653A1 (en)	2005-08-12	2007-02-22	Takeda Pharmaceutical Company Limited	Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
WO2007029587A1 (ja)	2005-09-05	2007-03-15	Dainippon Sumitomo Pharma Co., Ltd.	βセクレターゼ阻害剤
WO2007081534A2 (en) *	2005-12-22	2007-07-19	Pfizer Products Inc	Method of producing catalytically active bace2 enzymes
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
US8344002B2 (en)	2007-06-22	2013-01-01	Yoshiaki Kiso	Compound having β-secretase inhibitory activity
US8222264B2 (en)	2007-07-06	2012-07-17	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
CA2699787A1 (en) *	2007-09-24	2009-04-02	Comentis, Inc.	(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
AU2008343855B2 (en)	2007-12-21	2013-08-15	Amgen Inc.	Anti-amyloid antibodies and uses thereof
EP2303926A1 (de)	2008-06-20	2011-04-06	Oklahoma Medical Research Foundation	Immunogene memapsin-2-?-sekretasepeptide und anwendungsvergsverfahren
TW201020244A (en)	2008-11-14	2010-06-01	Astrazeneca Ab	New compounds
EP2281824A1 (de)	2009-08-07	2011-02-09	Noscira, S.A.	Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
US8956859B1 (en)	2010-08-13	2015-02-17	Aviex Technologies Llc	Compositions and methods for determining successful immunization by one or more vaccines
CN103228674B (zh)	2010-11-10	2019-07-05	霍夫曼-拉罗奇有限公司	用于神经疾病免疫疗法的方法和组合物
EP2643299B1 (de)	2010-11-22	2016-06-22	Noscira, S.A.	Bipyridinsulfonamidderivate zur behandlung von neurodegenerativen erkrankungen oder zuständen
UY34365A (es)	2011-10-07	2013-05-31	Takeda Pharmaceutical	Compuestos heterociclicos
BR112014029597A2 (pt)	2012-05-30	2017-11-07	Comentis Inc	compostos de cromano
EP2927229B1 (de)	2012-10-16	2018-09-05	Takeda Pharmaceutical Company Limited	Zur vorbeugung oder behandlung von neurodegenerativen erkrankungen oder epilepsie geeignete benzol-kondensierte fünfgliedrige stickstoff enthaltende heteroaromatische verbindungen
HUE039922T2 (hu)	2012-12-11	2019-02-28	Takeda Pharmaceuticals Co	Heterociklusos vegyületek
US9624184B2 (en)	2013-04-04	2017-04-18	Takeda Pharmaceutical Company Limited	Heterocyclic compound
EP2982666B1 (de)	2013-04-04	2019-08-07	Takeda Pharmaceutical Company Limited	Heterocyclische verbindung
EP3152198B1 (de)	2014-06-09	2019-02-27	Takeda Pharmaceutical Company Limited	Radioaktiv markierte verbindungen
JP6993228B2 (ja)	2014-11-19	2022-03-03	ジェネンテック，インコーポレイテッド	抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
CN107108745B (zh)	2014-11-19	2021-01-12	基因泰克公司	抗bace1的抗体和其用于神经疾病免疫疗法的用途
WO2017040808A1 (en) *	2015-09-03	2017-03-09	Contact Effect, Inc.	Management of tenant locations in multi-tenant environments
RS65984B1 (sr)	2016-02-04	2024-10-31	Takeda Pharmaceuticals Co	Supstituisano piperidinsko jedinjenje kao agonist oreksina tipa 2, za lečenje narkolepsije
US9919021B2 (en) *	2016-04-15	2018-03-20	Ibet—Instituto De Biologia Experimental E Tecnológica	Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions
WO2018164191A1 (ja)	2017-03-08	2018-09-13	武田薬品工業株式会社	置換ピロリジン化合物およびその用途
JP7012703B2 (ja)	2017-03-08	2022-02-14	武田薬品工業株式会社	置換ピロリジン化合物およびその用途
ES2973672T3 (es)	2017-07-28	2024-06-21	Takeda Pharmaceuticals Co	Compuesto heterocíclico
AU2018312326B2 (en)	2017-08-03	2023-06-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
WO2019027003A1 (ja)	2017-08-03	2019-02-07	武田薬品工業株式会社	複素環化合物およびその用途
TW202003519A (zh)	2018-03-28	2020-01-16	日商武田藥品工業股份有限公司	雜環化合物及其用途
CN108588040B (zh) *	2018-06-08	2021-06-15	中国医学科学院病原生物学研究所	重组MtMetRS、其晶体及它们在制备抗结核药物中的应用
WO2020004536A1 (ja)	2018-06-29	2020-01-02	武田薬品工業株式会社	複素環化合物およびその用途
WO2020004537A1 (ja)	2018-06-29	2020-01-02	武田薬品工業株式会社	複素環化合物およびその用途
US12091410B2 (en)	2018-12-12	2024-09-17	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JP7379374B2 (ja)	2018-12-12	2023-11-14	武田薬品工業株式会社	複素環化合物
MA54823A (fr)	2019-01-24	2022-04-27	Takeda Pharmaceuticals Co	Composé hétérocyclique et son utilisation
EP3917616A1 (de)	2019-01-31	2021-12-08	Takeda Pharmaceutical Company Limited	Heterocyclische verbindung und verwendung davon
CN114555083A (zh)	2019-09-13	2022-05-27	武田药品工业株式会社	食欲素2受体激动剂用于治疗过度嗜睡的用途
KR20220062012A (ko)	2019-09-13	2022-05-13	다케다 야쿠힌 고교 가부시키가이샤	기면증 치료에 사용하기 위한 tak-925
JP2021080177A (ja)	2019-11-14	2021-05-27	武田薬品工業株式会社	複素環化合物及びその用途
BR112022010323A2 (pt)	2019-11-27	2022-08-16	Takeda Pharmaceuticals Co	Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
JP2021183586A (ja)	2020-05-22	2021-12-02	武田薬品工業株式会社	複素環化合物
JP2021183587A (ja)	2020-05-22	2021-12-02	武田薬品工業株式会社	複素環化合物
WO2022190060A1 (en)	2021-03-12	2022-09-15	Takeda Pharmaceutical Company Limited	An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
WO2023090268A1 (ja)	2021-11-17	2023-05-25	武田薬品工業株式会社	細胞の製造方法
EP4508027A1 (de)	2022-04-12	2025-02-19	Takeda Pharmaceutical Company Limited	Heterocyclische verbindung
JP7592226B1 (ja)	2022-10-31	2024-11-29	武田薬品工業株式会社	複素環化合物
WO2024116086A1 (en)	2022-11-30	2024-06-06	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
TW202444345A (zh)	2023-03-16	2024-11-16	日商武田藥品工業股份有限公司	大環雜環化合物及其用途

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US111365A (en) *		1871-01-31		Improvement in combined rocking sofas and bedsteads
US55459A (en) *		1866-06-12		Improvement in artificial legs
US72050A (en) *		1867-12-10		Improvement in horse hiy-foeks
US81634A (en) *		1868-09-01		Improved kailway-switch
US159991A (en) *		1875-02-16		Improvement in shoe-tips
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) *	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4391904A (en) *	1979-12-26	1983-07-05	Syva Company	Test strip kits in immunoassays and compositions therein
US4501728A (en) *	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en) *	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4945050A (en) *	1984-11-13	1990-07-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) *	1984-11-13	1991-07-30	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) *	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en) *	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5219740A (en) *	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
US5132405A (en) *	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US4985544A (en)	1987-08-04	1991-01-15	Kyowa Hakko Kogyo Co., Ltd.	Process for renaturing fish growth hormone
DE10399031I1 (de)	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
US5591624A (en) *	1988-03-21	1997-01-07	Chiron Viagene, Inc.	Retroviral packaging cell lines
US4923967A (en) *	1988-09-26	1990-05-08	Eli Lilly And Company	Purification and refolding of recombinant proteins
GB8823869D0 (en) *	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
AU648261B2 (en)	1989-08-18	1994-04-21	Novartis Vaccines And Diagnostics, Inc.	Recombinant retroviruses delivering vector constructs to target cells
US5221607A (en)	1989-09-18	1993-06-22	Scios Nova Inc.	Assays and reagents for amyloid deposition
US5286634A (en) *	1989-09-28	1994-02-15	Stadler Joan K	Synergistic method for host cell transformation
JP3056782B2 (ja)	1989-11-03	2000-06-26	ヴァンダービルトユニバーシティ	標的器官内での遺伝子の発現用医薬組成物
FR2658432B1 (fr)	1990-02-22	1994-07-01	Medgenix Group Sa	Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5279833A (en) *	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
US5235043A (en) *	1990-04-06	1993-08-10	Synergen, Inc.	Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5204253A (en) *	1990-05-29	1993-04-20	E. I. Du Pont De Nemours And Company	Method and apparatus for introducing biological substances into living cells
US5308854A (en) *	1990-06-18	1994-05-03	Merck & Co., Inc.	Inhibitors of HIV reverse transcriptase
US5252463A (en)	1990-06-22	1993-10-12	The Du Pont Merck Pharmaceutical Company	Clipsin, a chymotrypsin-like protease and method of using same
AU8200191A (en)	1990-07-09	1992-02-04	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en)	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
US5200339A (en)	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (de) *	1990-08-29	2005-07-27	GenPharm International, Inc.	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) *	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5192668A (en) *	1990-10-11	1993-03-09	Merck & Co., Inc.	Synthesis of protease inhibitor
US5187074A (en) *	1990-10-11	1993-02-16	Merck & Co., Inc.	Method of hydroxylation with ATCC 55086
US5173414A (en) *	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
AU663725B2 (en)	1991-08-20	1995-10-19	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993008184A1 (en) *	1991-10-23	1993-04-29	Merck & Co., Inc.	Hiv protease inhibitors
US5413999A (en) *	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
IL105793A0 (en)	1992-05-28	1993-09-22	Lilly Co Eli	Protease and related dna compounds
US5587308A (en)	1992-06-02	1996-12-24	The United States Of America As Represented By The Department Of Health & Human Services	Modified adeno-associated virus vector capable of expression from a novel promoter
WO1993024640A2 (en)	1992-06-04	1993-12-09	The Regents Of The University Of California	Methods and compositions for in vivo gene therapy
US5665720A (en) *	1992-08-07	1997-09-09	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
AU680921B2 (en)	1993-05-17	1997-08-14	Regents Of The University Of California, The	Ribozyme gene therapy for HIV infection and AIDS
US5804566A (en) *	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) *	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US6015686A (en) *	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
WO1995010281A1 (en) *	1993-10-13	1995-04-20	Merck & Co., Inc.	Combination therapy for hiv infection
US5739118A (en) *	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
US5476874A (en) *	1994-06-22	1995-12-19	Merck & Co., Inc.	New HIV protease inhibitors
US5736524A (en) *	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5986054A (en)	1995-04-28	1999-11-16	The Hospital For Sick Children, Hsc Research And Development Limited Partnership	Genetic sequences and proteins related to alzheimer's disease
US5922687A (en) *	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
US5744346A (en)	1995-06-07	1998-04-28	Athena Neurosciences, Inc.	β-secretase
WO1996040885A2 (en)	1995-06-07	1996-12-19	Athena Neurosciences, Inc.	β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US6329163B1 (en)	1995-06-07	2001-12-11	Elan Pharmaceuticals, Inc.	Assays for detecting β-secretase inhibition
US6221645B1 (en) *	1995-06-07	2001-04-24	Elan Pharmaceuticals, Inc.	β-secretase antibody
US5978740A (en)	1995-08-09	1999-11-02	Vertex Pharmaceuticals Incorporated	Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
JP2000506375A (ja)	1996-01-26	2000-05-30	エイチエスシーリサーチアンドデベロップメントリミテッドパートナーシップ	アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
US5846978A (en) *	1996-05-02	1998-12-08	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
EP0812916A3 (de)	1996-06-14	1998-12-09	Smithkline Beecham Corporation	Cathepsin K Gen
DE19641180A1 (de)	1996-09-24	1998-03-26	Schering Ag	Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
AU4589297A (en)	1996-10-07	1998-05-05	Scios Inc.	Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
WO1998021589A1 (en)	1996-11-15	1998-05-22	The Trustees Of The University Of Pennsylvania	Screening for modulators of amyloid processing
US6207710B1 (en) *	1996-11-22	2001-03-27	Elan Pharmaceuticals, Inc.	Compounds for inhibiting β-amyloid peptide release and/or its synthesis
WO1998026059A1 (en)	1996-12-11	1998-06-18	Athena Neurosciences, Inc.	Beta-secretase isolated from human 293 cells
GB9701684D0 (en) *	1997-01-28	1997-03-19	Smithkline Beecham Plc	Novel compounds
US6077682A (en)	1998-03-19	2000-06-20	University Of Medicine And Dentistry Of New Jersey	Methods of identifying inhibitors of sensor histidine kinases through rational drug design
WO1999051752A1 (fr)	1998-03-31	1999-10-14	Chugai Seiyaku Kabushiki Kaisha	LIGNEE CELLULAIRE N'EXPRIMANT PAS UNE ACTIVITE DE β-SECRETASE
AU4045599A (en)	1998-06-05	1999-12-30	Aventis Pharma S.A.	Polypeptides with beta-secretase type activity
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6699671B1 (en) *	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en) *	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CA2343004A1 (en) *	1998-09-24	2000-03-30	Pharmacia & Upjohn Company	Alzheimer's disease secretase
US6245884B1 (en) *	1998-10-16	2001-06-12	Vivian Y. H. Hook	Secretases related to alzheimer's dementia
US6313268B1 (en)	1998-10-16	2001-11-06	Vivian Y. H. Hook	Secretases related to Alzheimer's dementia
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
GB2364059B (en) *	1999-02-10	2004-01-14	Elan Pharm Inc	Beta-Secretase enzyme compositions and methods
AU3770800A (en) *	1999-03-26	2000-10-16	Amgen, Inc.	Beta secretase genes and polypeptides
EP1192177A1 (de)	1999-06-15	2002-04-03	Elan Pharmaceuticals, Inc.	Statin-abstammende tetrapeptide als inhibitoren der beta-secretase
JP4484410B2 (ja) *	1999-06-28	2010-06-16	オクラホマメディカルリサーチファウンデーション	メマプシン２のインヒビターおよびその使用
EP1496124A1 (de)	1999-06-28	2005-01-12	Oklahoma Medical Research Foundation	Katalytisch wirksame rekombinierte Memapsin und Verfahren zur Verwendung davon
AR025754A1 (es)	1999-09-23	2002-12-11	Pharmacia & Upjohn Co Llc	Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos
US6361975B1 (en) *	1999-11-16	2002-03-26	Smithkline Beecham Corporation	Mouse aspartic secretase-2(mASP-2)
US6291223B1 (en) *	1999-11-23	2001-09-18	Smithkline Beecham Corporation	Mouse aspartic secretase-1 (mASP1)
ES2287044T3 (es) *	2000-01-25	2007-12-16	Oklahoma Medical Research Foundation	Procedimiento universal para el replegamiento de proteinas recombinantes.
ATE343562T1 (de)	2000-03-23	2006-11-15	Elan Pharm Inc	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6713276B2 (en) *	2000-06-28	2004-03-30	Scios, Inc.	Modulation of Aβ levels by β-secretase BACE2
EP1319179B1 (de)	2000-07-19	2008-03-05	Genisphere Inc.	Verfahren zur erkennung und zum assay von nukleinsäuresequenzen
AU2001281250A1 (en)	2000-08-11	2002-02-25	The Brigham And Women's Hospital, Inc.	(hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
EP1327143B1 (de) *	2000-09-22	2007-02-28	Wyeth	Kristallstruktur von bace und verwendungen dafür
WO2002047466A2 (en)	2000-10-27	2002-06-20	The Johns Hopkins University School Of Medicine	Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
CA2433446A1 (en)	2000-12-28	2002-07-11	Oklahoma Medical Research Foundation	Inhibitors of memapsin 2 and use thereof
US20040121947A1 (en)	2000-12-28	2004-06-24	Oklahoma Medical Research Foundation	Compounds which inhibit beta-secretase activity and methods of use thereof
AU2006279896A1 (en) *	2005-08-10	2007-02-22	Oklahoma Medical Research Foundation	Truncated memapsin 2 for use for treating Alzheimer's disease

2000
- 2000-06-27 JP JP2001507071A patent/JP4484410B2/ja not_active Expired - Fee Related
- 2000-06-27 WO PCT/US2000/017742 patent/WO2001000665A2/en active Application Filing
- 2000-06-27 JP JP2001507069A patent/JP5138851B2/ja not_active Expired - Fee Related
- 2000-06-27 CA CA002374610A patent/CA2374610A1/en not_active Abandoned
- 2000-06-27 AT AT00943236T patent/ATE482233T1/de not_active IP Right Cessation
- 2000-06-27 CN CN00810930A patent/CN1379819A/zh active Pending
- 2000-06-27 EP EP00943208A patent/EP1196609A2/de not_active Withdrawn
- 2000-06-27 DE DE60045005T patent/DE60045005D1/de not_active Expired - Lifetime
- 2000-06-27 WO PCT/US2000/017661 patent/WO2001000663A2/en not_active Application Discontinuation
- 2000-06-27 CA CA2374346A patent/CA2374346C/en not_active Expired - Fee Related
- 2000-06-27 AU AU57715/00A patent/AU5771500A/en not_active Abandoned
- 2000-06-27 EP EP00943236A patent/EP1194449B1/de not_active Expired - Lifetime
- 2000-06-27 AU AU57735/00A patent/AU5773500A/en not_active Abandoned
- 2000-06-27 US US09/604,608 patent/US6545127B1/en not_active Expired - Lifetime
2001
- 2001-02-28 US US09/795,903 patent/US20020164760A1/en not_active Abandoned
- 2001-04-30 US US09/845,226 patent/US20020115600A1/en not_active Abandoned
2004
- 2004-02-06 US US10/773,754 patent/US20040220079A1/en not_active Abandoned
- 2004-04-08 US US10/820,953 patent/US7244708B2/en not_active Expired - Fee Related
2007
- 2007-06-14 US US11/763,342 patent/US7678760B2/en not_active Expired - Fee Related
- 2007-08-03 US US11/888,920 patent/US7829669B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1379819A (zh)	2002-11-13
JP5138851B2 (ja)	2013-02-06
JP4484410B2 (ja)	2010-06-16
US7244708B2 (en)	2007-07-17
US6545127B1 (en)	2003-04-08
WO2001000665A2 (en)	2001-01-04
CA2374610A1 (en)	2001-01-04
US7678760B2 (en)	2010-03-16
WO2001000665A3 (en)	2001-09-27
US20080021196A1 (en)	2008-01-24
CA2374346A1 (en)	2001-01-04
US20040220079A1 (en)	2004-11-04
US20080112946A1 (en)	2008-05-15
AU5773500A (en)	2001-01-31
CA2374346C (en)	2010-06-22
US20040167075A1 (en)	2004-08-26
WO2001000663A3 (en)	2001-10-04
AU5771500A (en)	2001-01-31
EP1194449A2 (de)	2002-04-10
EP1194449B1 (de)	2010-09-22
US20020115600A1 (en)	2002-08-22
US7829669B2 (en)	2010-11-09
US20020164760A1 (en)	2002-11-07
JP2003503072A (ja)	2003-01-28
EP1196609A2 (de)	2002-04-17
JP2003506322A (ja)	2003-02-18
WO2001000665A9 (en)	2002-07-25
DE60045005D1 (de)	2010-11-04
WO2001000663A2 (en)	2001-01-04

Publication	Publication Date	Title
ATE482233T1 (de)	2010-10-15	Inhibitoren des memapsin 2 und ihre verwendung
Netzel-Arnett et al.	1991	Sequence specificities of human fibroblast and neutrophil collagenases.
EP0104041B1 (de)	1988-07-27	Enzyminhibitoren
Szelke et al.	1982	Potent new inhibitors of human renin
EP0462182A4 (en)	1992-08-12	Matrix metalloproteinase peptides: role in diagnosis and therapy
WO2002053594A3 (en)	2004-01-08	Inhibitors of memapsin 2 and use thereof
Kruger et al.	2004	Inhibition of the Staphylococcus aureus sortase transpeptidase SrtA by phosphinic peptidomimetics
Phillips et al.	1992	Guanidine derivatives restore activity to carboxypeptidase lacking arginine‐127
Bailey et al.	1994	A structural comparison of 21 inhibitor complexes of the aspartic proteinase from Endothia parasitica
Garcia-Echeverria et al.	1992	New intramolecularly quenched fluorogenic peptide substrates for the study of the kinetic specificity of papain
US8124372B2 (en)	2012-02-28	Selective enzymatic amidation of C-terminal esters or acids of peptides
Fotouhi et al.	1994	Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases.
Bourdel et al.	1996	New hydroxamate inhibitors of neurotensin‐degrading enzymes Synthesis and enzyme active‐site recognition
Powers et al.	1977	Inhibition of subtilisin BPN′ with peptide chloromethyl ketones
Berg et al.	1984	Formation of desTyr dynorphins 5–17 by a purified cytosolic aminopeptidase of rat brain
Krumme et al.	1998	Hydroxamate derivatives of substrate‐analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases 1
Morris et al.	2012	Prohormone-substrate peptide sequence recognition by peptidylglycine α-amidating monooxygenase and its reflection in increased glycolate inhibitor potency
Malfroy et al.	1987	New substrates for enkephalinase (neutral endopeptidase) based on fluorescence energy transfer
De Lisle Milton et al.	1993	Synthesis of proteins by chemical Ligation of unprotected peptide segments: mirror-image enzyme molecules, D-& L-HIV protease analogs
Ishikawa et al.	1999	Inhibition of thermolysin by 3-trimethylsilylalanine derivatives
Thomas et al.	1987	Distinguishing among protein kinases by substrate specificities
JPS60208999A (ja)	1985-10-21	チオペプトライド、およびそれを基質とするコラゲナ−ゼの測定法
EP2167673B1 (de)	2011-01-05	Verfahren zur umsetzung von c-terminalen peptidestern oder -säuren zu amiden unter verwendung von subtilisin in gegenwart von ammoniumsalzen
Jackson et al.	1988	A fluorimetric assay for aminopeptidase W
Grobelny et al.	1986	Inhibition of angiotensin converting enzyme by aldehyde and ketone substrate analogs

Legal Events

Date	Code	Title	Description
2011-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties